Aquilo Capital Management
Overview
Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. In our view, these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society. Marc Schneidman, Founder & CIO, has over 20 years of dedicated investing experience across the biotechnology universe.
Investment Focus
- Companies addressing urgent medical needs
- Early-stage biotech companies
- Innovative drug development firms
Portfolio Companies
Reach Aquilo Capital Management directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Aquilo Capital Management
What sectors does Aquilo Capital Management invest in?
Aquilo Capital Management invests in Biotechnology, AI, Health Tech and Data Science, and is based in San Francisco, California, United States. Aquilo Capital Management is listed as a vc in the ConnectSafely investor database.
What stage does Aquilo Capital Management invest at?
Aquilo Capital Management backs companies at Seed and Series A, writing cheques of 1M - 3M.
Which regions does Aquilo Capital Management invest in?
Aquilo Capital Management invests across United States, Denmark and Belgium.
What companies has Aquilo Capital Management invested in?
Aquilo Capital Management's portfolio includes Fate Therapeutics, Merus and Sensorion.
How do I contact Aquilo Capital Management?
Aquilo Capital Management's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
